Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PTC Therapeutics
Pharma
PTC, after rejections, will try again with Translarna at the FDA
PTC Therapeutics once again hopes to convince U.S. regulators of the value of its Duchenne muscular dystrophy therapy.
Eric Sagonowsky
Mar 19, 2024 10:10am
The top 10 drugs losing US exclusivity in 2024
Mar 11, 2024 3:00am
PTC's Emflaza to face generics this month post Aurobindo FDA nod
Feb 12, 2024 10:10am
PTC's re-examination bid for Translarna falls short in Europe
Jan 25, 2024 5:12pm
Royalty commits up to $1.5B for most of PTC's Evrysdi royalties
Oct 19, 2023 11:13am
Market withdrawal looms for PTC's DMD drug in Europe
Sep 15, 2023 10:42am